Company news

Vir Biotechnology, Inc. news in 2025

Vir Biotechnology, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology

December 17, 2025

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

December 15, 2025

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

November 18, 2025

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

November 8, 2025

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

November 6, 2025

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 4, 2025

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

November 2, 2025

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

October 21, 2025

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

October 8, 2025

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025

October 6, 2025

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 24, 2025

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 6, 2025

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

August 5, 2025

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 30, 2025

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

July 23, 2025

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

July 21, 2025

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

July 14, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 27, 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 19, 2025

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 11, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 8, 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 6, 2025

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

April 29, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

April 23, 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

March 20, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

March 12, 2025

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

February 18, 2025

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

February 11, 2025

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

January 7, 2025

Calls in 2025

Decks in 2025